Vistagen to Participate in the 45th Annual TD Cowen Healthcare Conference
Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company focused on neuroscience and pherine development, has announced its participation in the 45th Annual TD Cowen Healthcare Conference. The company's President and CEO, Shawn Singh, will deliver a corporate overview on Monday, March 3, 2025, at 2:30 p.m. Eastern Time.
The presentation will be accessible via webcast through the 'Events' page in the 'Investors' section of Vistagen's website. Investors and interested parties can access the replay of the webcast, which will be archived on the company's website after the event.
Vistagen (Nasdaq: VTGN), un'azienda biofarmaceutica in fase clinica focalizzata sulla neuroscienza e sullo sviluppo di feromoni, ha annunciato la sua partecipazione alla 45ª Conferenza Sanitaria Annuale TD Cowen. Il Presidente e CEO dell'azienda, Shawn Singh, presenterà una panoramica aziendale lunedì 3 marzo 2025, alle 14:30 ora orientale.
La presentazione sarà accessibile tramite webcast nella pagina 'Eventi' della sezione 'Investitori' del sito web di Vistagen. Gli investitori e le parti interessate potranno accedere alla registrazione del webcast, che sarà archiviata sul sito dell'azienda dopo l'evento.
Vistagen (Nasdaq: VTGN), una compañía biofarmacéutica en etapa clínica enfocada en la neurociencia y el desarrollo de feromonas, ha anunciado su participación en la 45ª Conferencia Anual de Salud TD Cowen. El Presidente y CEO de la compañía, Shawn Singh, ofrecerá una visión general de la empresa el lunes 3 de marzo de 2025, a las 2:30 p.m. hora del Este.
La presentación será accesible a través de un webcast en la página de 'Eventos' de la sección 'Inversores' del sitio web de Vistagen. Los inversores y partes interesadas podrán acceder a la grabación del webcast, que se archivará en el sitio web de la compañía después del evento.
비스타젠 (Nasdaq: VTGN)은 신경과학 및 페로몬 개발에 집중하는 임상 단계의 생명공학 회사로, 제45회 연례 TD 코웬 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 회사의 회장 겸 CEO인 Shawn Singh은 2025년 3월 3일 월요일, 동부 표준시 오후 2시 30분에 기업 개요를 발표할 예정입니다.
프레젠테이션은 비스타젠 웹사이트의 '투자자' 섹션의 '이벤트' 페이지를 통해 웹캐스트로 접근할 수 있습니다. 투자자 및 관심 있는 당사자는 이벤트 후 회사 웹사이트에 아카이브될 웹캐스트의 재생을 이용할 수 있습니다.
Vistagen (Nasdaq: VTGN), une entreprise biopharmaceutique en phase clinique axée sur les neurosciences et le développement de phéromones, a annoncé sa participation à la 45ème Conférence Annuelle TD Cowen sur la Santé. Le Président et CEO de l'entreprise, Shawn Singh, présentera un aperçu de l'entreprise le lundi 3 mars 2025, à 14h30, heure de l'Est.
La présentation sera accessible via un webinaire sur la page 'Événements' de la section 'Investisseurs' du site web de Vistagen. Les investisseurs et les parties intéressées pourront accéder à l'enregistrement du webinaire, qui sera archivé sur le site de l'entreprise après l'événement.
Vistagen (Nasdaq: VTGN), ein biopharmazeutisches Unternehmen in der klinischen Phase mit Schwerpunkt auf Neurowissenschaften und Pheromonentwicklung, hat seine Teilnahme an der 45. jährlichen TD Cowen Gesundheitskonferenz angekündigt. Der Präsident und CEO des Unternehmens, Shawn Singh, wird am Montag, den 3. März 2025, um 14:30 Uhr Eastern Time einen Unternehmensüberblick präsentieren.
Die Präsentation wird über einen Webcast auf der 'Veranstaltungen'-Seite im 'Investoren'-Bereich der Vistagen-Website zugänglich sein. Investoren und interessierte Parteien können die Aufzeichnung des Webcasts abrufen, die nach der Veranstaltung auf der Unternehmenswebsite archiviert wird.
- None.
- None.
Vistagen’s President and Chief Executive Officer, Shawn Singh, will present a corporate overview on Monday, March 3, 2025, at 2:30 p.m. Eastern Time. A webcast will be accessible through the “Events” page in the “Investors” section of the Company’s website at www.Vistagen.com. A replay of the webcast will be archived and available following the event.
About Vistagen
Headquartered in
Pherines specifically and selectively bind to peripheral receptors in human nasal chemosensory neurons, which activate olfactory bulb-to-brain neurocircuits without requiring systemic absorption or uptake into the brain to achieve desired therapeutic benefits and differentiated safety. Vistagen’s neuroscience pipeline also includes an oral prodrug with potential to impact certain neurological conditions involving the NMDA receptor. Vistagen is passionate about developing transformative treatment options to improve the lives of individuals underserved by the current standard of care for multiple highly prevalent indications, including social anxiety disorder, major depressive disorder, and vasomotor symptoms (hot flashes) associated with menopause. Connect at www.Vistagen.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250220897855/en/
Investor Inquiries:
Mark A. McPartland
markmcp@vistagen.com
Media Inquiries:
Michelle P.
mwellington@vistagen.com
Source: Vistagen
FAQ
When is Vistagen (VTGN) presenting at the TD Cowen Healthcare Conference?
How can investors access Vistagen's (VTGN) TD Cowen Conference presentation?
What is Vistagen's (VTGN) main focus in drug development?
Will there be a replay available of Vistagen's (VTGN) TD Cowen Conference presentation?
